Gastric Pentadecapeptide Body Protection Compound (abbreviated as BPC-157) is a name that may be familiar to proteome researchers. Studies suggest that it may aid in injury recovery, including sprains, muscle rips, and even stomach ulcers. There seems to be a lot of promise in BPC-157. However, how does BPC-157 relate to cancer? The supposed properties, action mechanisms, and cancer connection of BPC-157, as well as anything else researchers need to know, are laid out in this article. A comprehensive explanation of BPC-157 is provided below for those unfamiliar with it.

BPC-157 Peptide: Mechanism of Action

BPC-157, a pentadecapeptide, is made up of the 15 amino acids that bind peptide bonds together. Bepecin, PL-10, and PL 14736 are some of its alternate names. The peptide was first reported in 1993 in the Journal of Physiology. It is considered a synthetic peptide since it does not occur in nature but is created in a laboratory. However, it is not synthetic in the truest sense; it is sourced from a protein naturally occurring in the digestive tract. In its most basic form, it is a digestive system-produced protein.

In particular, there is substantial speculation that BPC-157 may promote healing and regeneration in experimental models. The word “BPC” really means “body protection compound,” it reflects what BPC is intended to do: protect and repair tissue.

BPC-157 Peptide and Cancer Cells

The overall understanding of BPC-157’s possible impact on cancer is somewhat restricted due to the lack of research on this topic. The cumulative impact of BPC-157 on cancer is unknown at this moment.

One study examined the impact of BPC-157 on the cardiovascular system. The results suggested that BPC may be a potent angiomodulatory substance influencing blood vessel formation. The study also purported that BPC may promote tissue healing by enhancing blood circulation. The process it employs is known as angiogenesis and vasculogenesis, which are technical words for forming new blood vessel networks.

Experts have highlighted the involvement of blood arteries in tumor formation. Some scientists have hypothesized that BPC-157 may promote the development of malignant tissues by forming new blood arteries in those areas. However, no research has suggested that BPC-157 might promote the formation of malignant tissues.

However, some studies have linked BPC-157 to a decreased risk of cancer, particlarly in the context of stomach cancer and malignancies in the stomach lining. The results are not yet final. Cancer may develop from lesions, ulcers, and other damage to the stomach lining.

According to one study, BPC-157 seems to support avoiding stomach lining lesions. A compound was given to the mice in the course of the research study, from which gastric lesions developed as a result. However, according to the study’s authors, BPC-157 seemed to considerably reduce stomach lesions. Research indicates that the risk of developing malignant stomach ulcers may be decreased with the exposure of BPC-157, which appeard to help to avoid stomach damage that may result in tumors.

Moreover, BPC-157 was speculated to inhibit skin cancer cells in a separate investigation. As suggested by some early findings, it seems to have the potential to slow down skin cancer progression. While the jury is yet out on BPC-157’s cancer-fighting potential, preliminary data suggests it may not be a total negative.

BPC-157 Peptide and the Side Effects of Cancer Treatment

Investigations purport that BPC-157 may alleviate some of the negative effects of cancer treatments. While certain chemotherapy compounds may do a good job of eliminating cancer cells, they may come with several unpleasant side effects, one of which is the development of stomach lesions.

One investigation analyzed the impact of BPC-157 on rats given a chemotherapy compound. The research indicated that animals with BPC appeared to have much fewer stomach lesions than rats without the peptide. Researchers hypothesized that BPC-157 may be impactful in the context of ulcers. The research results raise the possibility that this peptide might mitigate the gastrointestinal side effects of some chemotherapy compounds.

BPC-157 Peptide and Cachexia

Cachexia, sometimes called wasting syndrome, induces weight loss, mostly muscle and fat cells. Typically, it’s brought on by a more serious issue, such as cancer or AIDS. Approximately 50% of animal research models with cancerous cells experience cachexia at some point in the proliferation of the disease. This figure increases to 80% in instances of terminal cancer. Several additional consequences, including mortality, may arise from cachexia, making it a widely-studied area for researchers. Approximately 20% of cancer-related fatalities are thought to be cachexia-related. Although the specific mechanism is still unclear, BCP-157 has suggested promise in the context of cachexia caused by cancer in some animal studies.

Scientists interested in BPC-157 peptide for their studies are encouraged to visit the www.corepeptides.com website for the highest-quality, most affordable research compounds.

References

[i] Cox, H. D., Miller, G. D., & Eichner, D. (2017). Detection and in vitro metabolism of the confiscated peptides BPC-157 and MGF R23H. Drug Testing and Analysis, 9(10), 1490-1498. https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.21 52

[ii] Tkalčević, V. I., Čužić, S., Brajša, K., Mildner, B., Bokulić, A., Šitum, K., … & Parnham, M. J. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology, 570(1-3), 212-221. https://www.sciencedirect.com/science/article/pii/S0 014299907006206

[iii] Sikirić, P., Petek, M., Ručman, R., Seiwerth, S., Grabarević, Z., Rotkvić, I., … & Lang, N. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology[1]Paris, 87(5), 313-327. https://www.sciencedirect.com/science/article/pii/092842579390038U

[iv] Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC-157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153-159. doi:10.1007/s00441-019- 03016-8.

[v] Seiwerth, S., Brcic, L., Batelja Vuletic, L., Kolenc, D., Aralica, G., Misic, M., … & Sikiric, P. (2014). BPC-157 and blood vessels. Current Pharmaceutical Sesign, 20(7), 1121-1125. https://doi.org/10.2174/13816128113199990421

[vi] Hu, M., Zheng, P., Xie, Y., Boz, Z., Yu, Y., Tang, R., … & Huang, X. F. (2018). Propionate protects haloperidol[1]induced neurite lesions mediated by neuropeptide Y. Frontiers in Neuroscience, 12, 743. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196753/

[vii] The Link Between Gastric Ulcers and Stomach Cancer. Retrieved from https://www.oncnursingnews.com/view/the-link-between-gastric-ulcers-and-stomach-cancer

[viii] Bilic, I., Zoricic, I., Anic, T., Separovic, J., Stancic-Rokotov, D., Mikus, D., … & Perovic, D. (2001). Haloperidol-stomach lesions attenuation by pentadecapeptide BPC-157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. Life Sciences, 68(16), 1905-1912. https://doi.org/10.1016/S0024-3205(00)01025-0